Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Abstract Background Immune checkpoint inhibitor (ICI) therapy is increasingly used to treat non-small cell lung cancer (NSCLC). However, little attention has been given to the comparative analysis of adverse events (AEs) associated with different ICIs. Methods Disproportionality analysis and Bayesia...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
FDA adverse event reporting system
Non-small cell lung cancer
Immune checkpoint inhibitor
Immune-related adverse event
Pharmacovigilance signal
Matrix of pairwise comparison
Online Access:https://doi.org/10.1186/s12885-025-13614-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13614-1

Similar Items